(NASDAQ: ETNB) 89bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.87%.
89bio's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast ETNB's revenue for 2027 to be $9,413,060,055, with the lowest ETNB revenue forecast at $8,359,054,261, and the highest ETNB revenue forecast at $10,467,065,849. On average, 3 Wall Street analysts forecast ETNB's revenue for 2028 to be $46,888,075,480, with the lowest ETNB revenue forecast at $31,915,061,869, and the highest ETNB revenue forecast at $74,656,310,675.
In 2029, ETNB is forecast to generate $155,023,522,549 in revenue, with the lowest revenue forecast at $87,340,876,249 and the highest revenue forecast at $212,552,968,992.